TAG Mail 18 July 2019

**NSW TAG ACTIVITIES**

**Current email discussions and surveys**
- Jurisdictional formulary issues FYI and requests for information Ryzodeg and Tamsulosin – closes COB 22 July
- IV Magnesium - closes 19th July 2019

**Recent upload to members' section of website**
- Letter to NSW DTC Chairs regarding various issues and recommendations for action arising from recent email discussions - link

**Recruitment for NSW TAG Office Manager**
- Part time 21 hours per week, closes 21st July 2019 – link

**Research Recruitment**
NSW TAG and The University of Sydney are partnering in a research study (HREC approval 2018/ETH00701) on DTC decision-making. The aim of the project is to understand more about how DTCs make decisions about formularies, IPUs and medicines access programs, including the role of values, evidence and key stakeholders, and how possible conflicts of interest involving pharmaceutical companies are managed. Dr Lisa Parker, a researcher and practising medical clinician, would like to speak with a wide range of DTC members about their experiences and views. If you are interested in participating, please email a request for more information / expression of interest to: lisa.parker@sydney.edu.au

**OTHER NEWS (new additions in bold)**

**AHHA**
- Webinar: Improving the Patient Experience, 26th July 2019, 12:30PM - 01:30PM AEST - link

**Australian Commission on Safety and Quality in Health Care (ACSQHC)**
- Free online NSQHS Standards orientation course (enrolments close 30 October 2019) - link

**Australian Prescriber**
- Podcast Episode 53 Adolescent self-harm

**CEC**
- Third NSW AMS Forum - presentation slides now available - link
- Removal of CEC Sepsis Antibiotic Guidelines - from 31 July 2019 the Adult and Paediatric/Unwell Neonate Sepsis Antibiotic Guidelines will no longer be available on the CEC website - link

**Leading Health Systems Network (LHSN) (UK)**
- Webinar: Has Medication Safety Improved? Developing a Sustainable Health Intelligence system, 7th of August - link

**MJA Podcasts**
- Episode 29: Improving primary care for older Australians, with Prof Dimity Pond
**NSW Health Intranet**
- **Safety Notice 007/19** - High Concentration Insulin Products (Updated)

**Recruitment NSW Health**
- St George Hospital Director of Pharmacy position currently advertised until 19/07/2019

**TGA**
- Recall: A specific batch of Potassium Chloride 10mmol in 0.29% sodium chloride 100mL ‘minibags’ owing to possible microbial contamination. Batch: W66L5 Expiry: Jan 2020
- Updates to variations to prescription medicines guidance and e-form - [link](#)
- Webinar: Variations to prescription medicines: What's new? 24 July 12:30-1:30 AEST - [link](#)
- Return your unused opioids - [resource kit](#)

**Westmead Hospital Forum - Pharmacist Prescribing: Is This In The Patient's Best Interest? Thursday, 15 August 2019 from 5:45 pm to 7:30 pm (AEST), Westmead Hospital (Lecture Theatre 3), Darcy Road, Westmead – register [here](#)**

**CONSULTATIONS**

**Australian Commission on Safety and Quality in Health Care (ACSQHC)**
- Draft NSQHS Standards Aged care Module - Open for Consultation until 9 August 2019 - [link](#)

**REPORTS AND PUBLICATIONS – AUSTRALIA**

**Australian Commission on Safety and Quality in Health Care (ACSQHC)**
- The state of patient safety and quality in Australian hospitals 2019 – [link](#)
- Australian Atlas of Healthcare Variation Series - [link](#)
- Cognitive impairment resources - [link](#)

**Australian Institute for Health and Welfare (AIHW)**
- Mental health services in Australia - [link](#)
- Mortality Over Regions and Time (MORT) books – [link](#)
- General Record of Incidence of Mortality (GRIM) data – [link](#)
- Deaths in Australia – [link](#)

**SHPA**
- Position statement: Closing the loop of medication management in hospitals to improve patient safety with barcoding technology on unit dose packaging - [link](#)

**TGA**
- AusPARs
  -- Victoza™ (*Liraglutide*): indications expanded to include glycaemic control and prevention of cardiovascular events.
  -- Olumiant™ (*Baricitinib*) for moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately, or who are intolerant, to one or more DMARDs.

**REPORTS AND PUBLICATIONS – INTERNATIONAL**

**Agency for Healthcare Research and Quality (AHRQ) USA**
- Identifying potential medication discrepancies during medication reconciliation in the post-acute long-term care setting - [link](#)
- Serious misdiagnosis-related harms in malpractice claims: the "Big Three"—vascular events, infections, and cancers - [link](#)
- Clinician perspectives on electronic health records, communication, and patient safety across diverse medical oncology practices - [link](#)
- 'I think this medicine actually killed my wife': patient and family perspectives on shared decision-making to optimize medications and safety - [link](#)

**Care Quality Commission (UK)**
**MEDICATION SAFETY**

**electronic Medicines Compendium (eMC) (UK)**
- Revised SPCs
  -- Exviera™ (dasabuvir): now includes apalutamide, an enzyme inducer, in list of interacting drugs.
  -- Vemlidy™ (tenofovir alafenamide fumarate) and Biktarvy™ (bictegravir, emtricitabine, and tenofovir alafenamide): angioedema and urticaria added as adverse reactions.
  -- Venclyxto™ (venetoclax): includes a revision to the treatment recommendation for patients with hepatic impairment.
  -- Tafinlar™ (dabrafenib): Following dabrafenib cessation, effective methods of contraception must be used for a further 2 weeks (previously 1 week) and for 16 weeks (previously 4 months) following last dose of trametinib when given in combination with dabrafenib.
  -- Cetrotide™ (cetrorelix): The starting day of cetrorelix is dependent on number and size of growing follicles and/or amount of circulating oestradiol. Start of cetrolix may be delayed in absence of follicular growth but experience is based on starting day 5 or 6 of stimulation.
  -- Benlysta™ (belimumab): addition of suicidal behaviour and suicidal ideation as an uncommon ADR.
  -- NeisVac-C™ (meningococcal group c polysaccharide conjugate vaccine adsorbed): includes a warning regarding the increased risk of invasive meningococcal disease in patients receiving eculizumab, due to the inhibition of terminal complement activation.
  -- PecFent™ (fentanyl) nasal spray: coma added as an adverse effect in overdose.
  -- Triumeq™ (dolutegravir, abacavir and lamivudine): Amended to remove references to interactions with telaprevir and dofetilide
  -- Kaletra™ (lopinavir with ritonavir): Now contraindicates concomitant use with neratinib owing to increased neratinib concentrations (due to CYP3A inhibition by lopinavir and ritonavir) which may increase the potential for serious and/or life-threatening reactions.

**EMA**
- PRAC recommends new measures to avoid dosing errors with methotrexate: includes restricting prescribing to specialists, making package warnings more prominent, and providing educational materials for patients and healthcare professionals. Tablets will only be provided in blister packs with removal of recommendations to split doses.
- EMA to review meningioma risk with cyproterone medicines: following a recent French study that suggests that risk of meningioma, although still very low, may be greater in those taking high doses of cyproterone for a long period.

**Institute for Safe Medication Practices (ISMP) USA**
- Medication Safety Alert! July 18, 2019
  -- New Recommendations to Improve Drug Allergy Capture and Clinical Decision Support
  -- PROLIA-UDENYCA look-alike update
  -- Fatal error due to PAXIL-TREXALL sound-alike error
  -- Cybersecurity issues with subcutaneous insulin pump

**Medicines and Healthcare products Regulatory Agency (MHRA) UK**
- Febuxostat (Adenuric™): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease
- Tocilizumab (RoActemra™): rare risk of serious liver injury including cases requiring transplantation
- Rivaroxaban (Xarelto™): reminder that 15 mg and 20 mg tablets should be taken with food. MHRA has received a small number of reports suggesting lack of efficacy (thromboembolic events) in patients taking 15 mg or 20 mg rivaroxaban on an empty stomach.
- Tocilizumab and hepatotoxicity - serious drug-induced liver injury, including acute liver failure, hepatitis and jaundice, have been observed with tocilizumab. Frequency of serious hepatotoxicity is rare, but in some cases liver transplant required - link

**PAPERS OF INTEREST**

**Arthritis and Rheumatology**
- A rare side effect of checkpoint inhibitor therapy: Nivolumab induced axial polyarthritis of the facet and costovertebral joints - link

**American Journal of Health-System Pharmacy (AHJP)**
- Direct oral anticoagulants in patients with cancer - link
- ASHP national survey of pharmacy practice in hospital settings: Monitoring and patient education—2018 - link
- Workplace strategies to reduce pharmacy leadership burnout - link

**Annals of Internal Medicine**
- Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis - link
- Self-management of Epilepsy: A Systematic Review - link

**Australian Journal of Primary Health**
- Continuity of care: why it matters and what we can do - link
- Hunter and New England Diabetes Alliance: innovative and integrated diabetes care delivery in general practice - link
- Effectiveness of chronic obstructive pulmonary disease self-management interventions in primary care settings: a systematic review - link

**British Journal of Clinical Pharmacology**
- Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study - link
- Optimal route for administering tranexamic acid in primary unilateral total hip arthroplasty: Results from a multicenter cohort study - link
- The relative lethal toxicity of pharmaceutical and illicit substances: A 16-year study of the Greater Newcastle Hunter Area, Australia – link

**British Medical Journal (BMJ)**
- Pre-eclampsia: pathophysiology and clinical implications - link
- Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices - link
- Prevalence, severity, and nature of preventable patient harm across medical care settings: systematic review and meta-analysis – link
- Spending on World Health Organization essential medicines in Medicare Part D, 2011-15: retrospective cost analysis – link
- Brief review: Potential of ketamine to be first of new generation of rapid acting antidepressants - link

**Canadian Medical Association Journal (CMAJ)**
- Incidence of infections associated with oral glucocorticoid dose in people diagnosed with polymyalgia rheumatica or giant cell arteritis: a cohort study in England – link

**Circulation**
- Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial - link

**Cochrane**
- Human albumin infusion for treating oedema in people with nephrotic syndrome - link

**Diabetes Care**
- Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Fractures among Patients with Type 2 Diabetes - link
- Successful Treatment of Immune Checkpoint Inhibitor–Induced Diabetes Mellitus with Infliximab – case report - link

**European Journal of Hospital Pharmacy**
- National audit of antidote stocking in UK emergency departments - link
- Meropenem, rifampicin and gentamicin combination therapy in a patient with complicated urinary tract infection caused by extreme drug-resistant P. aeruginosa - link
- Multicentre experience of home omalizumab treatment for chronic spontaneous urticaria - link
- Wipe-sampling procedure optimisation for the determination of 23 antineoplastic drugs used in the hospital pharmacy - link

**Internal Medicine Journal**
- Audit-based measures of overuse of medical care in Australian hospital practice - link
- Prospective review to evaluate the impact of medication changes recommended by consultant geriatricians - link

**JAMA**
- Association Between State-Mandated Protocolized Sepsis Care and In-hospital Mortality Among Adults with Sepsis – link

**JAMA Cardiology**
- Systolic Blood Pressure and Risk of Valvular Heart Disease - link

**JAMA Internal Medicine**
- Association between Electronic Cigarette Use and Smoking Reduction in France - link
- Nabiximols for the Treatment of Cannabis Dependence: A Randomized Clinical Trial - link
- Prevalence of Inappropriateness of Parenteral Vitamin B12 Administration in Ontario, Canada - link
- Association of Mirabegron with the Risk of Arrhythmia in Adult Patients 66 Years or Older—A Population-Based Cohort Study - link

**JAMA Network Open**
- Cognitive and Motor Outcomes of Children with Prenatal Opioid Exposure: A Systematic Review and Meta-analysis - link
- Development and Validation of a Bedside Risk Assessment for Sustained Prescription Opioid Use after Surgery - link

**JAMA Neurology**
- Association of Obesity with Multiple Sclerosis Risk and Response to First-line Disease Modifying Drugs in Children - link

**JAMA Oncology**
- Pembrolizumab after Completion of Locally Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer: A Phase 2 Trial - link

**Journal of Clinical Nursing**
- Nurse-led post-discharge telephone follow-up calls: A mixed study systematic review – link

**Journal of Clinical Oncology**
- Trials and Tribulations of Corrected QT Interval Monitoring in Oncology: Rationale for a Practice-Changing Standardized Approach - link

**Lancet**
- A blueprint for protecting physical health in people with mental illness - link
- Series: Catatonia
- Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis - link
- Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis - link

NSW TAG Mail 18 July 2019 Edition
- Alternative dosing guidelines to improve outcomes in childhood tuberculosis: a mathematical modelling study - link
- Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis – link

**Molecular Diversity Preservation International (MDPI) – Pharmacy Journal**
- The Basics of Penicillin Allergy: What A Clinician Should Know - link
- Balancing Assessment with "In-Service Practical Training": A Case Report on Collaborative Curriculum Design for Delivery in the Practice Setting - link
- "It Made a Difference to Me": A Comparative Case Study of Community Pharmacists' Care Planning Services in Primary Health Care – link

**Medical Journal of Australia**
- Polypharmacy among older Australians, 2006–2017: a population-based study - link
- Diagnosing and managing work-related mental health conditions in general practice: new Australian clinical practice guidelines- link
- Pulmonary embolism: update on diagnosis and management- link
- An updated review of lipid-modifying therapy- link
- Potentially suboptimal prescribing of medicines for older Aboriginal Australians in remote areas - link
- Medical students as interpreters in health care situations: “… it’s a grey area" - link

**New England Journal of Medicine**
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer - link
- C-Reactive Protein Testing to Guide Antibiotic Prescribing for COPD Exacerbations - link
- Review: Drug-Induced Liver Injury — Types and Phenotypes - link

**National Institute for Health Research (NIHR) - NIHR Signals**
- Levetiracetam is a useful alternative to phenytoin in stopping prolonged epileptic seizures in children

**Pain**
- Pharmacological interventions for chronic pain in children: an overview of systematic reviews - link

**Prescriber UK**
- Targeting dyslipidaemia to prevent cardiovascular disease - link
- Hypertension clinic drug choices: tips for pharmacist prescribers - link

**Stroke**
- Antiplatelet Therapy After Non-cardioembolic Stroke - link

**Therapeutics and Clinical Risk Management**
- Vitamin D supplementation for the prevention or depletion of side effects of therapy with alemtuzumab in multiple sclerosis - link
- SGLT2 inhibitors and the changing landscape for treatment of diabetes - link

**Upcoming Events**
(New additions listed in TAGMail - click here for the running list of other events)

**ARCS Annual Conference - Putting patients at the centre of healthcare**
6-8 August 2019, The ICC, Sydney – link

**Advanced Care Planning Symposium by SESLHD, SLHD, UNSW, UOW and UTS**
10 September 2019, 9-1pm, John B Reid Theatre, UNSW Sydney, register free here

**AHHA - Implementing Comprehensive Care Conference**
14th - 16th October, Rydges World Square, Sydney - link

In case you missed last week’s TAG Mail…
Please visit the website for a cumulative listing.
The purpose of TAG Mail is to assist TAG members to identify and share relevant information for their professional practice. **Members are encouraged to routinely forward TAG Mail to others who they believe would benefit from this information such as colleagues in the same hospital department.** TAG Mail as a standing agenda item in clinical pharmacists’ and other clinicians’ meetings may help facilitate discussion of contemporary and emerging medicines and practice.

You are receiving this email because you or a workplace colleague has requested TAG Mail. NSW TAG analyses uptake of TAG Mail (email openings and clicks on specific contents) in order to optimise the TAG Mail service for our members and colleagues. By requesting TAG Mail, you are also agreeing to have your data (email address, country of abode) captured. All information obtained is used in accordance with NSW Health Privacy Policy. Please contact NSW TAG at nswtag@stvincents.com.au if you have any questions regarding this.